The majority of the rebates received from drug manufacturers are kept by pharmacy benefit managers (PBMs), which do not use the funds to reduce […]
PBMs’ rebates don’t reach patients, analysis finds Read More »
The PD-1 inhibitor tislelizumab “met the primary endpoint of non-inferior overall survival (OS) versus sorafenib” in the global Phase 3 trial as a first-line
Every year, bad weather events around the globe are exacerbated and new records are broken, a Nature study about climate change states. Extreme heat
Climate change exacerbates infectious disease, finds new study Read More »
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for a monkeypox vaccine that allow five-fold the number of
Monkeypox vaccine EUA will increase available doses Read More »
A new bacteria has made a home in the Gulf Coast region and scientists are not happy. Burkholderia pseudomallei is typically endemic to much
Deadly bacteria found for the first time on the Gulf Coast – and it won’t be the last Read More »
Pharmaceutical and biotech giant Pfizer joined by specialty vaccine company Valneva announced on Tuesday that they’ve started Phase 3 clinical study for Vaccine Against
Pfizer-Valneva’s Lyme disease vaccine enters phase 3 amid rising incidence Read More »
In a $5.4 billion deal that will boost its rare disease treatment business, Pfizer is buying the pioneer in treatments for sickle cell disease,
Global Blood Therapeutics acquisition to boost Pfizer’s sickle cell pipeline Read More »
Lyme disease is on the rise in rural America. There has been a 357% increase in the prevalence of Lyme disease in rural areas
Lyme disease increases but biotech battles back Read More »
As part of its $740 billion reconciliation deal, the Senate on Sunday, August 7, passed legislation with drug price controls. The Inflation Reduction Act,
Senate passes drug price controls; legislation would kill innovation, access Read More »
People with metastatic HER2-low breast cancer – whose tumors don’t have high levels of the protein – up until now had limited treatment options.
FDA approves Enhertu, first targeted therapy for HER2-low breast cancer Read More »
